5 May 2016 - NICE has today published final draft guidance recommending 2 new treatment options for some people who have conditions that put them at extremely high risk of heart attacks or strokes.

The draft guidance recommends alirocumab (Praluent, Sanofi) and evolocumab (Repatha, Amgen) for adults with primary hypercholesterolaemia or mixed dyslipidaemia to help reduce their risk of cardiovascular disease.

The drugs are recommended for people with these conditions whose cholesterol levels are not controlled adequately using other drugs such as statins, or who can’t tolerate statins because of their side effects or have another condition which means they can’t take them.

For more details, go to: https://www.nice.org.uk/news/press-and-media/nice-draft-guidance-recommends-new-drugs-for-cholesterol-disorder